Protein stability play Cedilla launches with $56.2M series A

Third Rock Ventures launched Cedilla Therapeutics Inc. (Cambridge, Mass.) with a tranched $56.2 million series A round. Details regarding the tranches were not disclosed.

Cedilla is developing small molecules that target processes upstream of the ubiquitin proteasome pathway in order to stabilize or degrade target proteins (see BioCentury, April 24)...